Skip to content
  • Access/Contact
  • JP
  • Members Only

Institute for Vaccine Research and Development(IVReD), Institute for Integrated Innovations

  • Career
  • About Us
  • Message from Director
  • Organization
  • Public Relations
  • Division of Vaccine Development
  • Division of Biological Response Analysis
  • Division of Vaccinology for Clinical Development
  • Division of Research Support
  • Advisor to the Director
  • Our Members
  • New Achievement
  • Publications -FY2024-
    • Publications -FY2023-
    • Publications -FY2022-
  • Latest Rumor Surveillance
  • Information as of May 30, 2025
  • Information as of May 23, 2025
  • Information as of May 16, 2025
  • Information as of May 7, 2025
  • Information as of May 1, 2025
  • Information as of April 23, 2025
  • Information as of April 7, 2025
  • Rumor Surveillance 2025-2026
  • Rumor Surveillance 2023-2024

New Achievement

    • CTLA-4
    • PD-L1
    Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs
    May 20, 2025
    • SARS-CoV-2
    • COVID-19
    Malabaricone C isolated from edible plants as a potential inhibitor of SARS-CoV-2 infection
    Apr 21, 2025
    • 脂質ナノ粒子
    Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery
    Apr 17, 2025
Show List
Back to top
  • Share by Facebook
  • Share by Twitter
  • Share by LINE
  • Access/Contact
  • Site Policy
  • Members Only
Institute for Vaccine Research and Development(IVReD), Institute for Integrated Innovations

We use cookies to improve our website for users' usability and experience. To accept cookies, click “Accept”.